Adma Biologics (ADMA) Shares Outstanding (Diluted Average) (2020 - 2025)

Adma Biologics has reported Shares Outstanding (Diluted Average) for 6 years, with the latest figure at $244.9 million in Q4 2025.

• For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 0.64% year-over-year to $244.9 million; the trailing twelve-month figure through Dec 2025 stood at $244.9 million (up 0.64% YoY), and the FY2025 full-year result was $244.9 million, up 0.64% from the prior year.
• Shares Outstanding (Diluted Average) for Q4 2025 stood at $244.9 million, roughly flat from $245.5 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $248.6 million in Q2 2025, with the low at $115.7 million in Q1 2021.
• Historically, Shares Outstanding (Diluted Average) has averaged $207.5 million across 5 years, with a median of $223.1 million in 2023.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Diluted Average) soared 69.35% — and 2025, when it rose 0.28%.
• Adma Biologics' Shares Outstanding (Diluted Average) stood at $139.6 million in 2021, then jumped by 41.77% to $197.9 million in 2022, then increased by 13.19% to $224.0 million in 2023, then advanced by 8.65% to $243.3 million in 2024, then climbed by 0.64% to $244.9 million in 2025.
• The last three Shares Outstanding (Diluted Average) figures came in at $244.9 million (Q4 2025), $245.5 million (Q3 2025), and $248.6 million (Q2 2025), per Business Quant data.